Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia

被引:83
|
作者
Gunnarsson, Rebeqa [1 ,2 ]
Mansouri, Larry
Isaksson, Anders [3 ]
Goransson, Hanna [3 ]
Cahill, Nicola
Jansson, Mattias
Rasmussen, Markus [3 ]
Lundin, Jeanette [4 ,5 ]
Norin, Stefan [4 ]
Buhl, Anne Mette [6 ]
Smedby, Karin Ekstrom [7 ]
Hjalgrim, Henrik [8 ]
Karlsson, Karin [2 ]
Jurlander, Jesper [6 ]
Geisler, Christian [6 ]
Juliusson, Gunnar [2 ]
Rosenquist, Richard
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden
[2] Lund Univ, Stem Cell Ctr, Dept Lab Med, Lund, Sweden
[3] Uppsala Univ, Dept Med Sci Canc Pharmacol & Informat, SE-75185 Uppsala, Sweden
[4] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden
[6] Rigshosp, Dept Hematol, Leukemia Lab, DK-2100 Copenhagen, Denmark
[7] Karolinska Inst, Clin Epidemiol Unit, Dept Med, Stockholm, Sweden
[8] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2011年 / 96卷 / 08期
基金
瑞典研究理事会;
关键词
chronic lymphocytic leukemia; SNP-array; genomic aberrations; CNN-LOH; clonal evolution; CLONAL EVOLUTION; CHROMOSOMAL-ABERRATIONS; DISEASE PROGRESSION; EARLY-STAGE; SNP ARRAYS; DELETION; RISK; SURVIVAL; 13Q14; ABNORMALITIES;
D O I
10.3324/haematol.2010.039768
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-resolution genomic microarrays enable simultaneous detection of copy-number aberrations such as the known recurrent aberrations in chronic lymphocytic leukemia [del(11q), del(13q), del(17p) and trisomy 12], and copy-number neutral loss of heterozygosity. Moreover, comparison of genomic profiles from sequential patients' samples allows detection of clonal evolution. Design and Methods We screened samples from 369 patients with newly diagnosed chronic lymphocytic leukemia from a population-based cohort using 250K single nucleotide polymorphism-arrays. Clonal evolution was evaluated in 59 follow-up samples obtained after 5-9 years. Results At diagnosis, copy-number aberrations were identified in 90% of patients; 70% carried known recurrent alterations, including del(13q) (55%), trisomy 12 (10.5%), del(11q) (10%), and del(17p) (4%). Additional recurrent aberrations were detected on chromosomes 2 (1.9%), 4 (1.4%), 8 (1.6%) and 14 (1.6%). Thirteen patients (3.5%) displayed recurrent copy-number neutral loss of heterozygosity on 13q, of whom 11 had concurrent homozygous del(13q). Genomic complexity and large 13q deletions correlated with inferior outcome, while the former was linked to poor-prognostic aberrations. In the follow-up study, clonal evolution developed in 8/24 (33%) patients with unmutated IGHV, and in 4/25 (16%) IGHV-mutated and treated patients. In contrast, untreated patients with mutated IGHV (n=10) did not acquire additional aberrations. The most common secondary event, del(13q), was detected in 6/12 (50%) of all patients with acquired alterations. Interestingly, aberrations on, for example, chromosome 6q, 8p, 9p and 10q developed exclusively in patients with unmutated IGHV. Conclusions Whole-genome screening revealed a high frequency of genomic aberrations in newly diagnosed chronic lymphocytic leukemia. Clonal evolution was associated with other markers of aggressive disease and commonly included the known recurrent aberrations.
引用
收藏
页码:1161 / 1169
页数:9
相关论文
共 50 条
  • [41] Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia
    Kay, Neil E.
    LaPlant, Betsy R.
    Pettinger, Adam M.
    Call, Timothy G.
    Leis, Jose F.
    Ding, Wei
    Parikh, Sameer A.
    Conte, Michael J.
    Bowen, Deborah A.
    Shanafelt, Tait D.
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (04) : 337 - 349
  • [42] Changing diagnosis during follow-up
    Moreno, T.
    Ferreira, J.
    Ribeiro, M.
    Levy-Gomes, A.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S139 - S139
  • [43] Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization
    Hosoya, N
    Sanada, M
    Nannya, Y
    Nakazaki, K
    Wang, LL
    Hangaishi, A
    Kurokawa, M
    Chiba, S
    Ogawa, S
    GENES CHROMOSOMES & CANCER, 2006, 45 (05): : 482 - 494
  • [44] Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up
    Chelysheva, Ekaterina
    Abruzzese, Elisabetta
    Rea, Delphine
    Kim, Dong-Wook
    Kazakbaeva, Khamida
    Saliev, Sukhrob
    Kotlyarchuk, Konstantin
    Polushkina, Evgenia
    Shmakov, Roman
    Chabaeva, Julia
    Kulikov, Sergei M.
    Turkina, Anna G.
    BLOOD, 2018, 132
  • [45] Array Comparative Genomic Hybridization: A Better Alternative for Genomic Profiling and Prognosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Leon, Annette
    Sevilla, Deborah
    Marino, Joseph M.
    Moreno, Kenneth D.
    Obrera, Rev
    Lee, PoShing
    Ye, Donjiu
    Talwar, Jotica
    Persad, Rajendra
    Villamil, Cesar
    Maya, Melissa
    Mehta, Nirav
    Kemel, Yelena
    Weisberger, James
    BLOOD, 2012, 120 (21)
  • [46] ALLOTRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKAEMIA A FOLLOW-UP OF 12 PATIENTS
    Holowiecki, J. H.
    Krawczyk-Kulis, M.
    Stella-Holowiecka, B.
    Czerw, T.
    Wojnar, J.
    Markiewicz, M.
    Giebel, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 493 - 493
  • [47] Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Baccarani, M.
    Pileri, S.
    Steegmann, J. -L.
    Muller, M.
    Soverini, S.
    Dreyling, M.
    Grp, E. S. M. O. Guidelines Working
    ANNALS OF ONCOLOGY, 2012, 23 : 72 - 77
  • [48] Acalabrutinib with obinutuzumab in treatmentnaive and relapsed/refractory chronic lymphocytic leukemia: 3-year follow-up
    Woyach, Jennifer
    Rogers, Kerry
    Bhat, Seema
    Blachly, James
    Jianfar, Mojgan
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng
    Wang, Min Hui
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2020, 61 : 17 - 18
  • [49] Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia
    Zinzani, PL
    Bendandi, M
    Magagnoli, M
    Albertini, P
    Rondelli, D
    Stefoni, V
    Tani, M
    Tura, S
    HAEMATOLOGICA, 2000, 85 (11) : 1135 - 1139
  • [50] MEMBRANOUS NEPHROPATHY ASSOCIATED WITH B-CHRONIC LYMPHOCYTIC-LEUKEMIA - A 5 YEARS OF FOLLOW-UP
    BAGLIN, A
    PRINSEAU, J
    ALTERESCU, R
    FRANC, B
    NOCHY, D
    GOGUEL, A
    ANNALES DE MEDECINE INTERNE, 1987, 138 (03): : 189 - 192